A Multi-dose Ingestible Capsule to Address the Misuse of Antibiotics

Introducing MultiTab™, a new a multi-compartment drug delivery system being developed by SmartTab. One example of a major benefit to a multi-compartment drug delivery approach is the misuse of antibiotics today.  Misusing antibiotics is rampant in our society without consideration of its implications. Most antibiotics are prescribed for 7 – 10 days, yet many times individuals will feel better at day 3-4 and stop taking their antibiotics.

So what happens when you don't finish your course of antibiotics?  Many of us are guilty of this. When we get ill, we visit the doctor for prescription of antibiotics, then we take them for some time and we stop when we feel we are better without completing the dosage-neglecting the, thoroughly researched, time and dosage recommendations.

World Health Organization research proves that stopping treatment without completion of dosage is risky as it doesn’t get all the bacteria that causes the illness killed, which can result in future illness. No prescription is made without examination and the prescription is based on the best evidence for what will kill all bacteria. Completing antibiotic dosages, even if you get better during the treatment, will completely rid your body of the causative bacteria and reduce the risk of the bacteria building resistance against the antibiotics and other drugs with similar compositions.

“OUR TECHNOLOGY IS WORKING ON THE PHARMACY OF THE FUTURE.”

— ROBERT NIICHEL, SMARTTAB™ FOUNDER AND CEO

How the multi-compartment MultiTab™ can patient's drug regimen. When you believe you are better, moving around your daily activities with drugs might not be an easy option and sometimes, it is possible to forget the medication at home or not being with the drugs at the appropriate time you were supposed to take it due to circumstances. This is exactly what our technology will integrate, a lasting solution in order to help reduce or completely eliminate the breed of resistant bacteria in our society.

Our multi-compartment MultiTab™ would stay in the GI tract for a period of 7-10 days and release the medication at the appropriate time every day by using a smartphone or smartwatch with a timer and a triggering mechanism. This would not only improve patient outcomes, but it would also prevent the misuse of antibiotics leading to superbugs.

The SmartTab platform's first application TargetTab™ has just completed successful pre-clinical animal studies. This is a big milestone for us because now we have demonstrated success of our actual functioning system. It paves a way for us to complete additional studies, human clinical studies, and on our way to FDA submission and approval.